^
    Back
    Association details:
    Biomarker:HMGA2 expression
    Cancer:Colorectal Cancer
    Drug:oxaliplatin (DNA synthesis inhibitor, DNA cross linking agent)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    Source:
    PLoS One
    Title:

    TGM2, HMGA2, FXYD3, and LGALS4 genes as biomarkers in acquired oxaliplatin resistance of human colorectal cancer: A systems biology approach

    Published date:
    08/03/2023
    Excerpt:
    The present study aims to identify the key genes involved in acquired oxaliplatin-resistant in CRC by confirming the oxaliplatin resistance index (OX-RI)….To this aim, differentially expressed genes (DEGs) between the sensitive- and oxaliplatin-resistant CRC cells related to the two identified data series were obtained....Based on the results, TGM2, HMGA2, FXYD3, and LGALS4 genes are related to oxaliplatin-resistant CRC and may serve as novel therapeutic targets.
    DOI:
    https://doi.org/10.1371/journal.pone.0289535